Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05731947 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
A Phase 1 study of Colorectal Cancer and Solid Tumors, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 6
- Study locations
NCT05731947 is a Phase 1 study of Colorectal Cancer and Solid Tumors that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 42 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT05731947, a Phase 1 study of Colorectal Cancer and Solid Tumors, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of revumenib in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.
Conditions Studied
Interventions
- DRUG Chemotherapy
- DRUG Revumenib
Study Locations (6)
Arizona
- Honor Health Research Institute - Scottsdale
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Memorial Sloan Kettering Cancer Center - Manhattan
Ohio
- Gabrail Cancer Center - Canton
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Virginia
- Inova Schar Cancer Institute - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05731947
The ClinicalTrials.gov registry entry for NCT05731947 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Chemotherapy is the first listed.
NCT05731947 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT05731947 about?
NCT05731947 is a clinical study titled "Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors". This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of revumenib in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.
What is the current status of trial NCT05731947?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2023-04-04. Estimated completion is 2025-06-30.
What conditions does trial NCT05731947 study?
This clinical trial studies the following conditions: Colorectal Cancer, Solid Tumors.
What interventions are being tested in trial NCT05731947?
The interventions under investigation include: Chemotherapy (DRUG), Revumenib (DRUG).
Who is sponsoring clinical trial NCT05731947?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05731947 being conducted?
This trial has 6 study locations across Arizona, Massachusetts, New York, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.